Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 7/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068246 | 1.00 | GSK3B (0.46) | GSK3BMGLLMCHR1P4HBPRSS1 | |
| SCHEMBL2701471 | 1.00 | GSK3B (0.46) | GSK3BMGLLMCHR1P4HBPRSS1 | |
| SCHEMBL1066999 | 0.88 | PDCD1 (0.46) | GSK3BMGLLMCHR1P4HBPRSS1 | |
| SCHEMBL1067001 | 0.88 | PDCD1 (0.46) | GSK3BMGLLMCHR1P4HBPRSS1 | |
| SCHEMBL1067003 | 0.88 | PDCD1 (0.46) | GSK3BMGLLMCHR1P4HBPRSS1 | |
| SCHEMBL1067886 | 0.81 | MGLL (0.47) | MGLLMCHR1P4HBPRSS1ACR | |
| SCHEMBL1067887 | 0.81 | MGLL (0.47) | MGLLMCHR1P4HBPRSS1ACR | |
| SCHEMBL1067883 | 0.81 | MGLL (0.47) | MGLLMCHR1P4HBPRSS1ACR | |
| SCHEMBL20463239 | 0.79 | MTNR1A (0.39) | — | |
| SCHEMBL28577855 | 0.74 | MGLL (0.50) | GSK3BMGLLP4HBPRSS1ACR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | GSK3B 2528/4885MGLL 1910/4885MCHR1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.